Chapter 23: Medical Mycology

Medical mycology examines the complex relationships between fungi and human health, focusing on how fungal organisms establish infections through three primary mechanisms of pathogenic colonization. Obligate parasitic fungi such as dermatophytes have evolved specialized adaptations to target keratinized tissues, while dimorphic soil fungi undergo morphological transformation to survive within the human body environment, and opportunistic saprobes capitalize on immunocompromised states to cause disease. The field organizes fungal infections into three anatomical categories based on depth of tissue penetration and clinical severity. Cutaneous mycoses affect the skin surface and hair, with dermatophytes including Epidermophyton, Microsporum, and Trichophyton causing ringworm and nail infections through keratin digestion and inflammatory irritant production. Malassezia globosa, a basidiomycete yeast, colonizes the scalp by metabolizing sebaceous oils and produces dandruff and dermatitis. Candida albicans, normally present as a commensal organism in the gastrointestinal tract, undergoes pathogenic overgrowth causing mucosal and cutaneous disease. Subcutaneous mycoses develop when environmental fungi penetrate traumatized skin barriers, producing localized infections such as chromoblastomycosis with its characteristic warty growths, mycetoma with granular discharge patterns, and sporotrichosis with lymphatic spread. Systemic mycoses represent the most severe category, caused by dimorphic pathogens including Histoplasma capsulatum from bat or bird guano, Coccidioides immitis endemic to arid soils, Paracoccidioides brasiliensis in South America, and Blastomyces dermatitidis, along with opportunistic agents that flourish in immunocompromised patients. Cryptococcus neoformans causes cryptococcal meningitis, zygomycetes cause mucormycosis in diabetic and burn patients, and Aspergillus fumigatus produces allergic and invasive pulmonary disease. Immunocompromised individuals, particularly those with AIDS, face heightened vulnerability to multiple opportunistic fungal pathogens that serve as clinical diagnostic markers of immunosuppression. Modern antifungal therapeutics have evolved from early potassium iodide and amphotericin B treatments to include polyene compounds, azole derivatives, allylamines, and echinocandin agents, though treatment selection depends on infection type, location, and patient immune status, with significant side effects remaining a clinical consideration.